Cargando…

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

IMPORTANCE: Immunotherapy checkpoint inhibitors have generated considerable interest because of durable responses in a number of hitherto intractable tumor types. OBJECTIVE: To estimate the percentage of patients with cancer in the United States who are eligible for and respond to checkpoint inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haslam, Alyson, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503493/ https://www.ncbi.nlm.nih.gov/pubmed/31050774 http://dx.doi.org/10.1001/jamanetworkopen.2019.2535

Ejemplares similares

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Estimation of US patients with cancer who may respond to cytotoxic chemotherapy
por: Maldonado, Edward B, et al.
Publicado: (2020)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
por: Bhatt, Anjali, et al.
Publicado: (2023)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals
por: Buck, Eva, et al.
Publicado: (2023)

Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
por: Haslam, Alyson, et al.
Publicado: (2020)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases
por: Dickson, Sean
Publicado: (2020)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
por: Palsson, Olafur, et al.
Publicado: (2019)

Factors Associated With Disparities in Hospital Readmission Rates Among US Adults Dually Eligible for Medicare and Medicaid
por: Silvestri, David, et al.
Publicado: (2022)

Comparison of Income Eligibility for Medicaid vs Marketplace Coverage for Insurance Enrollment Among Low-Income US Adults
por: Bhanja, Aditi, et al.
Publicado: (2021)

Who dies where? Estimating the percentage of deaths that occur at home
por: Adair, Tim
Publicado: (2021)

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
por: Goldstein, Daniel A., et al.
Publicado: (2023)

Association of the Estimated Glomerular Filtration Rate With vs Without a Coefficient for Race With Time to Eligibility for Kidney Transplant
por: Zelnick, Leila R., et al.
Publicado: (2021)

Medical Reversals in Family Practice: A Review
por: Haslam, Alyson, et al.
Publicado: (2020)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature
por: Haslam, Alyson, et al.
Publicado: (2022)

The frequency of assessment of progression in randomized oncology clinical trials
por: Haslam, Alyson, et al.
Publicado: (2021)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

Analysis of Eligibility for Lung Cancer Screening by Race After 2021 Changes to US Preventive Services Task Force Screening Guidelines
por: Pinheiro, Laura C., et al.
Publicado: (2022)

Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
por: Ermer, Theresa, et al.
Publicado: (2022)

Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries
por: Hong, Young-Rock, et al.
Publicado: (2020)

Variation in HIV Transmission Behaviors Among People Who Use Drugs in Rural US Communities
por: Jenkins, Wiley D., et al.
Publicado: (2023)

Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review
por: Sharp, John, et al.
Publicado: (2021)

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use
por: Prasad, Vinay, et al.
Publicado: (2023)

Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force
por: Liu, Yu, et al.
Publicado: (2022)

Considerations for treatment duration in responders to immune checkpoint inhibitors
por: Marron, Thomas U, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i8m06esrps6de9rtum6a7i8kls